Authors: Hironori Fujii Hirotoshi Iihara Akio Suzuki Ryo Kobayashi Nobuhisa Matsuhashi Takao Takahashi Kazuhiro Yoshida Yoshinori Itoh
Publish Date: 2016/04/22
Volume: 77, Issue: 6, Pages: 1209-1215
Abstract
AntiEGFR monoclonal antibody is effective for KRAS wildtype metastatic colorectal cancer mCRC but frequently causes several adverse reactions including hypomagnesemia and skin disorders The present study was designed to investigate the relationship between the incidence of adverse reactions and therapeutic effects in mCRC patients receiving antiEGFR monoclonal antibody in combination with firstline chemotherapyFortythree mCRC patients who received cetuximab or panitumumab between April 2012 and December 2015 were the subjects of the present study All patients were pretreated with oral minocycline in combination with skin treatment using moisturizer for prevention of skin rash Hypomagnesemia and acneiform rash were graded according to the Common Terminology Criteria for Adverse Events version 30 Overall response rate ORR and time to treatment failure TTF were compared between patients with and without these adverse eventsThe incidence rates of hypomagnesemia and acneiform rash were 326 grade 1 209 grade 2 116 and 930 grade 1 419 grade 2 419 grade 3 93 respectively ORR was significantly higher in patients with hypomagnesemia than in those without it 714 vs 345 P = 0048 Median TTF tended to be longer though not significantly in patients with hypomagnesemia than in those without it However no significant difference in both ORR and median TTF was observed between patients with and without acneiform rash
Keywords: